Featured Story | Monday, June 29, 2020 Industry watchers and pharma critics have spent the past two months pitching their calculations on how Gilead Sciences would—and should—price remdesivir. Now, the guessing is over. And the finalized price means Gilead could still reap $2.3 billion in 2020 revenue from remdesivir, one analyst figures. read more |
| |
|---|
|
Top Stories Monday, June 29, 2020 As COVID-19 continues to impact the job market, new data from the Trump administration show that nearly 500,000 people signed up for coverage using HealthCare.gov through May. read more Monday, June 29, 2020 As COVID-19 continues to rampage across the globe, Brazil stands alongside the U.S. as the countries hardest hit with new infections and deaths. But AstraZeneca and its vaccine hopeful could be coming to save the day now that the drugmaker and Brazilian government have reached a new supply pact. read more Monday, June 29, 2020 Hyperimmune globulins work by giving patients a mix of antibodies produced by different kinds of immune cells, so they have multiple different antibodies against multiple different antigens on the virus. Morabito called it a “shotgun approach” that could help patients fight off COVID-19 while researchers are still learning about the disease. read more Monday, June 29, 2020 Top players in gene and cell therapy have mobilized behind the mission of turning the new technologies against COVID-19. Their efforts to perfect these therapies could help combat this pandemic, prevent future ones and eliminate viruses that have resisted more traditional treatments. read more Thursday, June 25, 2020 Google Health executive David Feinberg gave assurances Thursday that Google and Apple took a "privacy-first" approach to develop COVID-19 exposure notification technology. Feinberg said contact tracing apps could play a valuable role in preventing a renewed spread of the virus. The question is, will anyone else them? read more Sunday, June 28, 2020 Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more Monday, June 29, 2020 Gilead Sciences unveiled the long-awaited price for its antiviral COVID treatment remdesivir Monday. Beckman Coulter nabbed FDA approval to ship 30 million antibody tests per month. And a Takeda R&D chief talked up the company's recent collaboration to develop a hyperimmune therapy. read more Monday, June 29, 2020 As two of Germany’s brightest COVID-19 pandemic vaccine biotechs continue to speed on with their clinical work, both have seen big cash injections to help them—but from very different sources. read more Monday, June 29, 2020 Beckman Coulter received an FDA emergency authorization for its mass-produced coronavirus antibody test, with plans to deliver more than 30 million tests per month worldwide. read more Monday, June 29, 2020 Contract research organization PPD has boosted its COVID-19 research by adding five new molecular, serology and functional assays. read more |  | [Webinar] Mastering the Virtual Clinical Trial Now available on demand! This Fierce webinar will bring together executives with expertise in R&D and technology implementation to explain the potential benefits of virtual clinical trials, as well as the ins and outs of designing and running them. It will include representatives from companies that have completed virtual clinical trials successfully and can provide advice on what did and did not work. Watch now. |
|
|
